ArticleResearch and reports in urology2025
Impact of Age, TNM Stage, and Hospitalization on Bladder Cancer Survival: Evidence from a Hospital-Based Cohort in Eastern China.
Article in Research and reports in urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial: Microbial biomarkers predicting BCG therapy response in non-muscle invasive bladder cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate survival outcomes and identify prognostic factors among bladder cancer patients. Patients and Methods: A total of 488 bladder cancer patients admitted between 2007 and 2017 were followed until December 31, 2020, using both active and passive follow-up. The Kaplan-Meier method was used to estimate observed survival (OS), with group comparisons performed using the Log rank test. Variables included sex, age group, number of hospital admissions, TNM stage, and geographic origin. Results: Of 488 patients, 485 (99.38%) were successfully followed. The majority were male (80.21%) with a mean age of 66.5 years. The average number of hospital admissions was 1.81. Overall 1-, 3-, 5-, and 10-year OS rates were 79.95%, 63.50%, 56.32%, and 45.54% for males, and 69.79%, 58.33%, 56.01%, and 56.01% for females, respectively (P = 0.697). Age significantly affected prognosis (P < 0.01), with 5-year OS declining from 66.67% (age ≤34) to 29.53% (≥80). Patients with ≥3 admissions had worse survival (44.87%) than those with one (61.93%) or two admissions (58.97%) (P < 0.01). TNM stage was strongly with survival: 5-year OS rates were 86.43% (Stage I), 55.48% (Stage II), 38.25% (Stage III), and 13.85% (Stage IV) (P < 0.01). Regional differences were not statistically significant (P > 0.05). Conclusion: Advanced age and late-stage diagnosis were associated with poorer survival, while early-stage detection correlated with better outcomes. These findings underscore the importance of early screening, timely treatment, and comprehensive care strategies to improve bladder cancer survival, especially in resource-limited settings. Limitations include single-center design and absence of multivariate adjustment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.